Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Utility of FebriDx in early identification of possible COVID19 MESHD infection

    Authors: Nawazish Karim; Muhammad Zubair Ashraf; Muhammad Naeem; Tahir Anwar; Hnin Aung; Srikumar Mallik; Eleni Avraam; Sidra Kiran; Sareesh Bandapaati; Faisal Khan; Georgios Tsaknis; Raja V. Reddy

    doi:10.21203/rs.3.rs-25802/v1 Date: 2020-04-27 Source: ResearchSquare

    Background Reliable differentiation between uncomplicated and self-limiting acute respiratory tract infections MESHD (ARIs) and more severe bacterial respiratory tract infections MESHD remains challenging, due to the non-specific clinical manifestations in both systemic bacterial or viral infections MESHD. The current COVID-19 pandemic MESHD COVID-19 pandemic MESHD is putting extraordinary strain on healthcare resources. To date, molecular testing is available but has a long turnaround time and therefore cannot provide results at the point-of-care, leading to a delay in results thereby exposing patients to cross-infection MESHD and delay in diagnosis (1-3). Methods We prospectively evaluated the utility of FebriDx®, a point-of-care fingerstick blood test that can differentiate viral from bacterial ARIs through simultaneous detection of both Myxovirus-resistance protein A ( MxA HGNC) and C-reactive protein HGNC ( CRP HGNC), in rapidly determining viral cases requiring immediate isolation and confirmatory molecular testing, from non-infectious patients or bacterial infections MESHD that require antibacterial therapy.Results 75 consecutive patients were assessed and 48 eligible cases were tested with FebriDx®. Overall, 35 patients had FebriDx® test viral positive. All 35 patients had either positive rt-PCR (n=30) for COVID-19 MESHD or clinical picture highly suggestive of COVID-19 MESHD infection (PPV of 100% in a pandemic situation)[AB1] . In the 13 cases it was viral negative, rRT-PCR was also negative in all cases. In one case of LRTI, it was not possible to determine the exact cause of infection and a viral infection couldn’t be excluded. Including this patient, the NPV was 12/13 (92%) exceeding the NPV of rRt-PCR at 71% (12/17). Sensitivity was conservatively calculated at 97% (35/36) compared to 85.7% (30[RS2] /35) for rRt-PCR.  Similarly the specificity of both FebriDx®and rRt-PCR was 100% (12/12).Conclusions In the current COVID-19 MESHD, FebriDx® shows potential as a reliable POC test and a proxy marker of COVID-19 MESHD infection amongst inpatients in a secondary care setting.  [AB1]35/35 equates to a sensitivity and specificity of 100% for COVID, would you be willing to say that instead of ‘near 100% ppv)? [RS2]I believe PCR was 85.7% (30/35), because PCR only detects the COVID cases

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.